Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

BACKGROUND: Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Gambale, Elisabetta, Giorgione, Roberta, Santini, Daniele, Stellato, Marco, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Basso, Umberto, Bimbatti, Davide, Doni, Laura, Nesi, Gabriella, Bersanelli, Melissa, Buti, Sebastiano, De Giorgi, Ugo, Galli, Luca, Sbrana, Andrea, Conca, Raffaele, Carella, Claudia, Naglieri, Emanuele, Pignata, Sandro, Procopio, Giuseppe, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385587/
https://www.ncbi.nlm.nih.gov/pubmed/35312175
http://dx.doi.org/10.1002/cam4.4681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385587/
https://www.ncbi.nlm.nih.gov/pubmed/35312175
http://dx.doi.org/10.1002/cam4.4681

Ejemplares similares